- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Right Turn Show - Decoding the Use of Dapagliflozin and its Combinations with Metformin and Sitagliptin in Specialty Care Settings - Video
Overview
Presenting Episode 2 of the Right Turn Show, in this episode, insights from leading experts are explored on the practical application of dapagliflozin and its combinations in speciality settings. The previous episode focused on the consideration of dapagliflozin in specialty care settings. Building on that, this episode delves into the various Fixed Dose Combinations (FDCs) of dapagliflozin.
Dapagliflozin remains a preferred therapy among clinicians for managing Type 2 Diabetes Mellitus (T2DM), while also offering significant benefits in the treatment of heart failure and chronic kidney disease (CKD).
This episode features two distinguished experts, Dr J.C. Mohan, a prominent cardiologist and Chairman of the Institute of Heart & Vascular Diseases at Jaipur Golden Hospital, New Delhi. Prof. Abdul Hamid Zargar, a leading endocrinologist renowned for his expertise in diabetes and endocrine care from Srinagar, Jammu & Kashmir.
In this episode they will address the following key questions:
1) Prioritization of therapies monotherapy, dual FDC, or triple FDC for patients in cardiology and endocrinology settings
2) Differentiate between using Dapagliflozin monotherapy, Dapagliflozin Sitagliptin dual FDC, and Dapagliflozin Sitagliptin Metformin triple FDC in clinical practice
3) Potential benefits of dapagliflozin, sitagliptin and metformin